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Abstract
Background: Cognitive-Behavioural Family Therapy (CBFT) can be an effective psychological
approach for children with β-thalassaemia major, increasing compliance to treatment, lessening the
emotional burden of disease, and improving the quality of life of caregivers.
Design and methods: Twenty-eight β-thalassaemic major children that followed CBFT for one
year were compared with twenty-eight age-matched healthy children, focusing particularly on
behavioural, mood, and temperamental characteristics as well as compliance with chelation,
assessed using the Child Behaviour Checklist (CBCL), Children's Depression Inventory (CDI),
Multidimensional Anxiety Scale for Children (MASC), and Emotionality, Activity, Sociability and
Shyness Scale (EAS). We also monitored the quality of life of caregiving mothers using the World
Health Organization Quality Of Life (WHOQOL-BREF) questionnaire. Data were analysed with
non-parametric standard descriptive statistics.
Results: 90% of β-Thalassaemic children showed good compliance with chelation therapy;
however they had significantly increased somatic complains, physical symptoms and separation
panic. Moreover, temperamental assessment revealed high emotionality and poor sociability in
treated thalassaemic children and in their mothers. Physical and psychological domains concerning
individual's overall perception of quality of life resulted impaired in mothers of β-thalassaemic
children.
Conclusion: CBFT can be a valid tool to increase the compliance with chelation therapy in β-
thalassaemic children; however, treated children continue to show an important emotional burden;
moreover, CBFT therapy seems not to have any positive impact on the quality of life of caregiving
mothers, who may therefore need additional psychological support.
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β-Thalassemia major is a disorder characterized by defec-
tive production of hemoglobin and excessive destruction
of red blood cells. Hemoglobin (Hb) is formed of four
protein subunits, two α and two β. Genetic mutations in
the gene encoding for the β subunits of the protein, result
in reduced or totally absent synthesis of the globin β-
chains, leading to the formation of abnormal hemoglobin
or even to the absence of β hemoglobin. This defect causes
an abnormal development of red blood cells and ulti-
mately anemia, which is the characteristic symptom of the
thalassemia. The disease is prevalent among Mediterra-
nean people; the highest frequency is found in the Greek
islands, in Italy (lower Pò valley, Sicily and Sardinia) and
in Asia, where the highest concentration of people carry-
ing the genetic mutations underlying thalassemia is found
in the Maldives.
The most severe form is the β-thalassemia major, which is
characterized by a severe microcytic, hypochromic anemia
(Cooley's anemia), whose symptoms appear usually
within the first 2 years of life. Infants become pale and
asthenic, have a poor appetite, grow slowly, and often
develop jaundice; spleen, liver, and heart may also be
enlarged. Adolescents with the most severe form may
experience delayed puberty. The usual treatment consists
of periodic blood transfusions, that can cause iron over-
load within tissues. Children on hypertransfusion regimes
will maintain normal growth up to puberty. Serum ferri-
tin gives an estimate of the total body iron; levels higher
than 2500 mg/l over a period of 15 years are considered a
risk factor for cardiac disease.
Desferrioxamine is the most widely used iron chelator
and it is shown to reduce hepatic iron and to improve
hepatic fibrosis and cardiac dysfunction. The toxic effects
of desferrioxamine are well documented. If iron chelation
is inadequate, deposition can occur in several endocrine
organs, thus leading to disease conditions such as diabetes
mellitus and hypogonadotrophic hypogonadism and
growth hormone deficiency, and less often, to hypothy-
roidism and hypoadrenalism. Bone marrow transplanta-
tion is a radical care option for β-thalassemia major, but it
can induce some complications, including chronic graft
versus host disease, mixed chimaerism, hepatic iron over-
load, cardiac disease and viral hepatitis [1,2].
In children, especially, β-thalassemia major and its com-
plications carry a significant psychological impact, caus-
ing emotional burden, hopelessness, and difficulty with
social integration. Thalassemic children have been
described to show impaired abstract reasoning, deficits of
language, attention, memory, constructional/visual spa-
tial skills, and executive functions, all of which are more
prominent in hemosiderotic subjects [3]. In most chil-
dren, low intelligence quotient appears to be correlated
with poor school performances and physical or social
restrictions for the severity and chronicity of the disease,
and not with age, sex, ferritin level, brainstem auditory,
visual and somatosensory evoked potentials, or motor
and sensory nerve conduction velocity [4,5].
Thalassemic children feel different from their peers and
elaborate negative thoughts about their life, guilt senses,
increased anxiety and low self-esteem; their behavioural
profile is similar to normal subjects, but many of them
can manifest severe psychosocial problems due to difficul-
ties in complying with the painful chelation; male
patients, in particular, show oppositional defiant disorder
[6-9]. Within the family, concerns for the future of the tha-
lassemic child may contribute to worsen the relationship
between members, and to increase marginalization and
isolation. A psychological support seems therefore to be
useful to reduce the emotional burden of β-thalassemia
major children and their families. Additionally, quality of
life, which is an index of health care defined as an individ-
ual's perception of their position in life in the context of
culture and value systems in which they live, and in rela-
tion to their goals, expectations, standards, and concerns,
is often limited by the chronic illness.
Even if in recent years the innovative therapeutic strategies
for thalassaemia major have greatly increased the life
expectancy, the fear for the disease itself and for the possi-
ble complications of invasive medical procedures still
affect the quality of life of the entire family. So far, only a
few studies have been conducted analyzing the quality of
life in β-thalassaemia, and these studies have employed
two instruments for the assessment of this parameter: one
derived from the WHOQOL-100 questionnaire, and
another one designed specifically for thalassemia to
assesses both psychosocial and clinical burden [10,11].
In our study we have structured a psychological support
for β-thalassaemia major children using Cognitive-behav-
ioural Family Therapy (CBFT), in order to facilitate the
adherence to iron chelation and to contain the emotional
burden. We have included caregiving mothers in CBFT
sessions as maternal participation could be a useful strat-
egy to improve mother/child communication, and ulti-
mately to promote a greater compliance to chelation
therapy and to improve the quality of their life [12]. To
prevent the development of clinically manifest psychoso-
cial morbidity and to improve the quality of life of the
family are, consequently, important goals in the treatment
of β-thalassaemia [13].
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in β-thalassaemia major children after a sessions pro-
gramme of CBFT;
2. To assess behaviour, mood, and temperament peculiar-
ities of patients, compared to healthy subjects;
3. To analyze quality of life (QoL) of caregiving mothers.
Methods
Study design
Twenty-eight outpatients with a diagnosis of β-thalassae-
mia major (aged 12.79 ± 3.57 years; 15 subjects > 13
years) were included in the study. Diagnosis of β-thalas-
saemia major was made in each patient before the age of
3 years old. These patients received an high haemo-trans-
fusional regimen and a chelation therapy with desferiox-
amine, which was infused subcutaneously 10–12 hours a
day for 5–6 days a week (25–50 mg/kg). Twenty-eight
healthy subjects (aged 12.52 ± 3.48 years;14 subjects > 13
years) were also enrolled from a database of children
attending a well-being paediatric clinic for routine checks.
Both thalassemic and healthy groups of children received
a comprehensive physical and neurological assessment,
including EEG and ophthalmological examinations. β-
thalassaemia major children were submitted to CBFT for
1 year with their mothers. CBFT was carried out according
to Dattilo and Montano [14], and CBFT sessions were
held by a psychologist twice a week for each month, often
overlapping with an hemo-transfusion or a laboratory
check-up. Each CBFT session lasted 45 minutes, with a
global duration of 900 min corresponding to 15 hours of
therapy for each pair. There was no attrition.
Specific targets of CBFT were:
1. to communicate informations on the biological aspects
and on the emotional impact of the disease; to increase
the knowledge of possible side-effects of the chelation
treatment as well as of myths and misconceptions about
the treatment itself;
2. to identify relevant psychosocial factors;
3. to manage and to minimize emotional suffering of tha-
lassemic children;
4. to improve mother/child communication to foster a
positive relationship;
5. to help patient and mother to cope with events occur-
ring in the family, and to realize that erroneous beliefs
could cause emotional distress.
After 1 year of CBFT, β-thalassaemia major children were
evaluated for compliance index (as a percentage), calcu-
lated as the ratio between days of administration of ther-
apy and days of prescription within the last 1 year; an
index higher than 75% indicated a good compliance. All
participants were also submitted to a battery of the follow-
ing psychological instruments for a comprehensive evalu-
ation of behaviour, mood, and temperament compared to
healthy subjects:
a) Wechsler Intelligence Scale for Children (WISC-IV) for
the intelligence quotient (IQ) [15].
b) Child Behaviour Checklist (CBCL), completed by the
parents rating behavioural and emotional problems along
two dimensions of 'internalising' symptoms such as anxi-
ety and depression, and 'externalising' symptoms, such as
aggression and hyperactivity. Raw scores on each clinical
factor were transformed to T-scores based on published
norms [16].
c) Multidimensional Anxiety Scale for Children (MASC),
completed by the child to score symptoms of anxiety
according to a 4-point Likert-style self-report scale. Sub-
factors include physical symptoms, harm avoidance,
social anxiety, and separation anxiety. Raw scores were
converted into standard T-scores [17].
d) Children's Depression Inventory (CDI), completed by
the child to rate symptoms of depression. The CDI is a
self-rating scale scored on three-point scale (0 absent; 1
moderate; 2 severe) reflecting severity of symptoms. Total
score ranges from 0 to 54; 19-point cut-off indicates the
threshold discriminating children at risk of depression
[18].
e) Emotionality Activity Sociability and Shyness (EAS)
Scale was administered to children and their caregiving
mothers to rate four temperamental traits: emotionality,
activity, sociability, and shyness. For each item the subject
was asked to rate the statement on a "5 point" Likert scale,
ranging from 0 (not characteristic or typical) to 5 (very
characteristic or typical) [19].
f) World Health Organization Quality Of Life (WHO-
QOL)-Bref questionnaire was administered to mothers of
β-thalassaemia major children and mothers of normal
subjects [11]. It has 26 items and four domains related to
quality of life: physical health, psychological health,
social relationships and environment, and two individual
items covering overall quality of life and general health.
Higher scores denote better QoL. The WHOQOL-Bref
domain scores showed good discriminant validity and
internal consistency of subscales evaluated by Cronbach's
alpha coefficients (alpha P ≥ 0.75). Data were analysedPage 3 of 6
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metric instrument Student's t-test. A two-tail p-value of <
.05 was used as the cut-off point of statistical significance.
Informed consent was obtained from children and their
mothers.
Results
Twenty-eight β-thalassaemic children submitted to CBFT
were compared to twenty-eight age-matched healthy sub-
jects. The two groups, statistically compared by a χ2 test,
were homogeneous for mean age, male/female ratio,
socio-economic status, education, and I.Q.. No family his-
tory of psychological illness was reported in any subject
and none of them showed any physical, neurological,
ophtalmological, or EEG alteration.
Compliance to treatment of β-thalassaemic children was
good in 25/28 patients (greater than 90%).
Compared to healthy subjects, β-thalassaemic children
displayed more somatic complaints as measured on the
CBCL (58.29 ± 7.37 vs. 53.32 ± 4.48, p = 0.004) and more
physical symptoms (48.79 ± 6.37 vs. 45.04 ± 3.52, p =
0.009) and separation panic (53.36 ± 10.31 vs. 48.18 ±
6.96, p = 0.032) as measured by the MASC. CDI scores
were not statistically different between β-thalassaemic
children and healthy subjects; however, in 3 patients CDI
scores exceeded the cut-off. On the EAS thalassemic
patients displayed high emotionality (p = 0.031) and low
sociability (p < 0.001); and their mothers displayed high
emotionality and shyness, and low sociability (table 1).
Responses to the WHOQOL-Bref questionnaire indicated
that mothers of β-thalassaemic children showed impair-
ment in the following domains: physical health, psycho-
logical health, quality of life and general health (table 2).
Discussion
β-thalassaemia is a chronic illness that causes excessive
psychological burden to children and their families as
clinical manifestations usually develop early in the life
and invasive procedures induce remarkable suffering [20].
Experience using continuous desferoxamine infusion
demonstrated that local reactions could result in inade-
quate compliance in many patients, higher morbidity,
and increased costs [21]. Distressed by the illness itself
and from iron chelation, thalassaemic subjects show fre-
quently maladaptive coping strategies and high levels of
anxiety with psychosocial dysfunction [22-27]. A psycho-
social support aimed at reducing emotional distress,
improving the compliance to chelation therapy, and
strengthening the coping strategies for a better integration
in daily life, is therefore necessary. Aydinok et al. reported
that the frequency of psychopathology is higher in thalas-
saemic subjects compared to the normal population; this
supports the need for thalassaemic patients and their par-
ents of a lifelong psychological support to prevent mental
health issues [7].
Our study was designed to verify the effectiveness of CBFT
in improving compliance to chelation therapy. Moreover
we sought to evaluate the influence of CBFT on the behav-
ioral, emotional, and temperamental profile of thalassae-
mic children (CBCL, MASC, CDI and EAS), and on the
quality of life of their caregiving mothers. 90% of the β-
thalassaemic major children included in the study had
good compliance, suggesting that CBFT could be effective
for this purpose. However the comparison with healthy
age-matched children revealed that β-thalassaemic major
children have higher scores on somatic complaints, phys-
ical symptoms, and separation panic, suggesting an emo-
tional burden. No relevant anomalies in lowered mood
were observed in β-thalassemic children. Higher emotion-
ality and reduced sociability were present in thalassaemic
children, and increased emotionality and shyness, along
with lower sociability, were present in their mothers. An
additional goal of the present study was to evaluate the
QoL of caregivers. QoL measures could provide helpful
information to the family. In caregivers of children with
sickle cell disease, another type of chronic hematopatho-
Table 1: EAS scores (mean ± SD) in β-thalassaemic major children and their mothers and in healthy subjects.
EAS for children β-Thalassaemic patients (28) Normal subjects (28) p-valuea
Emotionality 2.80 ± 0.91 2.29 ± 0.81 0.031
Activity 3.60 ± 0.74 3.69 ± 0.59 n.s.
Sociability 2.74 ± 0.51 3.50 ± 0.70 0.001
Shyness 2.60 ± 0.75 2.34 ± 0.49 n.s.
EAS for mothers
Emotionality 2.98 ± 0.71 2.40 ± 0.28 0.001
Activity 3.19 ± 0.61 3.25 ± 0.45 n.s.
Sociability 3.45 ± 0.52 4.13 ± 0.59 0.001
Shyness 2.63 ± 0.78 2.10 ± 0.69 0.009
a For statistical comparison student's t-test has been used.Page 4 of 6
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cantly lowered on all subscales in comparison with a
control group of the same socio-economic status [28]. We
have found, similarly, a significant impairment in moth-
ers of β-thalassaemic children in terms of physical health
(concerning energy and fatigue, pain and discomfort,
sleep and rest subscales), psychological health (bodily
image and appearance, feelings, self-esteem, thinking,
learning, memory and concentration subscales) and
domains assessing overall QoL. The awareness of the ill-
ness has been suggested as a possible factor influencing
both the compliance with treatment and the quality of life
of mothers. In fact, a previous study found that tha-
lassemic children and their parents, who were more con-
scious of the illness, were also more compliant with the
therapy, but also needed more psychological support,
being affected by depression, obsession, paranoia, and
hostility [7].
Our data agree with these studies, as mothers of our tha-
lassaemic well compliant children elaborated a painful
perception of the disease and showed impairment in
domains involved in physical health, psychological
health, quality of life and general health. Poor QoL of car-
egiving mothers could be explained by a sense of guilt for
having generated a child with a genetically determined
disease. CBFT could be considered as an appropriate
approach to β-thalassaemic children because it seems to
have a positive effect on the compliance with the chela-
tion therapy, thus improving the relation and communi-
cation with medical staff; however its role is questionable
for the complexity of the presenting symptoms both on
children and parents. Mothers often conceal their emo-
tional distress, and their attitude is generally overprotec-
tive towards the thalassemic children.
Despite some limitations, our study is provocative and
has potential implications for future research. However, it
should be viewed in the context of the following consid-
erations. 1. Endemic Countries in the Mediterranean
region have achieved 80–100% prevention of newly
affected births, by long-established control programs
based on avoiding the pregnancies in heterozygotic cou-
ples, and this has dramatically reduced the incidence of β-
thalassaemia major in Sicily: the small sample size of the
present study reflects these prevention strategies 2. Con-
sidering that all the patients were psychologically stressed,
we had to make the choice of including each of them in
the CBFT sessions, to ensure them the adequate support.
3. In order to assess the degree to which the effects of a
sustainable psychological support could influence the
experience of parenting a child with thalassaemia major,
a longitudinal study of changes over the life span of tha-
lassaemic people, to be started before the initiation of the
support therapy, becomes necessary.
Conclusion
The present study suggests that CBFT can be an additional
tool to approach the complexity of a chronic disease such
as β-thalassaemia major. The choice of CBFT can be can be
justified to improve the compliance to chelation therapy;
however certain psychological findings, such as somatic
complaints, physical symptoms, and separation panic in
β-thalassaemia major children are indicative of persistent
emotional burden, probably related to the fear for future
complications. Involvement of the mothers in the thera-
peutic setting can improve the relationship with child and
medical staff, but we also have to consider that in this case
the quality of life of mothers remains somewhat compro-
mised. This kind of therapy could therefore be combined
with additional psychological support.
Table 2: WHOQOL-Bref scores (mean ± SD) in mothers with β-thalassaemic major children vs. normal group mothers; Higher scores 
indicate a higher QOL.
Domains β-Thalassemia Group Mothers (N = 28) Normal Group mothers (N = 28) p-valuea
Physical Health 57.29 ± 11.47 68.45 ± 15.68 0.004
Psychologic Health 63.80 ± 9.22 69.59 ± 7.43 0.012
Social Relationships 74.01 ± 14.25 79.37 ± 10.01 0.109
Enviroment 48.54 ± 14.41 50.85 ± 1.47 0.402
Quality of Life 62.50 ± 15.96 77.98 ± 13.75 0.001
General Health 58.04 ± 19.31 71.43 ± 21.08 0.016
a For statistical comparison student's t-test has been used.Page 5 of 6
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